Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥3) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)

Autor:	Irena Rohr
Rok vydání:	2017
DOI:	10.26226/morressier.58f9ffb4d462b80290b5028b
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ed5d60797fb0a5a76f7350d2d87db6a0 https://doi.org/10.26226/morressier.58f9ffb4d462b80290b5028b Zobrazit plný text záznamu